All relevant data are within the paper and its Supporting Information files.

Introduction {#sec005}
============

The number of women with polycystic ovary syndrome (PCOS) has been continuously and rapidly increasing. Recent reports indicated that the prevalence of PCOS in women of reproductive age is 5--10% \[[@pone.0140565.ref001], [@pone.0140565.ref002]\]. About 50--70% of patients with PCOS have been confirmed to have insulin resistance and central obesity \[[@pone.0140565.ref003]--[@pone.0140565.ref005]\]. Both insulin resistance and central obesity predict the development of metabolic syndrome, which increases the risks of type 2 diabetes, hyperlipidemia, and cardiovascular disease \[[@pone.0140565.ref006]--[@pone.0140565.ref008]\]. Adipose tissue, especially visceral adipose tissue, is not only a fat storage depot but also an important endocrine organ, as it produces, synthesizes, and releases a number of bioactive proteins referred to as adipocytokines \[[@pone.0140565.ref009]\]. Recently, studies have demonstrated that adipocytokines are extensively implicated in the pathophysiological processes of metabolic disorders such as PCOS, insulin resistance, obesity, type 2 diabetes, and cardiovascular diseases \[[@pone.0140565.ref010]\]. Adiponectin is an adipocytokine synthesized in white adipose tissue. Its level is negatively correlated with obesity, insulin resistance, type 2 diabetes, coronary vascular diseases, and metabolic syndrome \[[@pone.0140565.ref011]--[@pone.0140565.ref013]\]. High adiponectin levels may reduce the risk of insulin resistance and type 2 diabetes \[[@pone.0140565.ref014]\]. Resistin, which contributes to insulin sensitivity, is another peptide secreted by the adipose tissue. Circulating resistin levels are increased in diet-induced and genetic forms of obesity animal models such as ob/ob and db/db mice. Serum resistin levels are decreased by using anti-diabetic drugs such as rosiglitazone \[[@pone.0140565.ref015]\]. Recent studies report a new adipocytokine, visfatin, also known as pre-B cell colony-enhancing factor, which is expressed in visceral lipid tissue and linked to metabolic syndrome. Studies have shown that visfatin expression is increased in individuals with abdominal obesity and type 2 diabetes \[[@pone.0140565.ref016]\]. Furthermore, leptin is a circulating hormone produced by adipocytes and is associated with insulin resistance in patients with PCOS \[[@pone.0140565.ref017], [@pone.0140565.ref018]\].

Metformin, a widely used insulin sensitizer, is an effective treatment of PCOS. It may improve ovulatory function in patients with PCOS, partly via weight loss or changes in body composition \[[@pone.0140565.ref019]\]. However, this hypothesis could not be confirmed with short-term treatment.

To understand how metformin improves the metabolic and hormonal disturbances in patients with PCOS, numerous studies have been conducted to determine the effect of metformin on adipocytokines in patients with PCOS, but their conclusions are far from uniform. Considering the large body of published evidence and amount of conflicting results, the primary purpose of the present study was to systematically review literature on the association between adipocytokines and metformin treatment in patients with PCOS in order to meta-analyze the best evidence available to provide high-quality data on the link between metformin treatment and adipocytokine levels in patients with PCOS.

Materials and Methods {#sec006}
=====================

Search strategy {#sec007}
---------------

We searched for English articles included in the SCI, PUBMED, EMBASE, and Elsevier databases. The following search terms were included: (visfatin AND metformin) AND (PCOS OR polycystic ovary syndrome)(adiponectin AND metformin) AND (PCOS OR polycystic ovary syndrome)(resistin AND metformin) AND (PCOS OR polycystic ovary syndrome)(leptin AND metformin) AND (PCOS OR polycystic ovary syndrome)

The computerized search was supplemented with a manual search of the bibliographies of all articles retrieved. Potentially relevant articles were assessed for inclusion based on prespecified inclusion and exclusion criteria.

Eligibility of relevant studies {#sec008}
-------------------------------

Studies that met the following criteria were included: All study subjects were limited to adults with PCOS diagnosed consistently by using either the Rotterdam \[[@pone.0140565.ref020]\] or National Institute of Health (NIH) criteria \[[@pone.0140565.ref021]\].The study reported adiponectin, leptin, resistin, or visfatin values obtained both before- and after metformin therapy.

Studies were excluded if they met the following criteria: The information available was not adequate for data extraction.Abstracts, letters to the editor, and case reports.

### Data extraction {#sec009}

Information from each study was extracted independently by 2 reviewers by using a standardized data extraction form. The general characteristics, methodology (PCOS definition and adiponectin/resistin/visfatin/leptin measurement method), and outcomes (both the total adiponectin/resistin/visfatin/leptin means and SDs before and after metformin administration) of each study were recorded, where available, and double-checked. Where appropriate, the data set was completed through communication with the authors. Disagreements were resolved by consensus.

### Statistical analysis {#sec010}

The meta-analysis was conducted by using STATA version 12.0 and Review manager 5.2. Standard mean differences (SMD) and 95% confidence intervals (CIs) of the adipocytokine levels were calculated for all eligible studies and combined by using appropriate fixed or random effects models. The Mantel-Haenszel analysis method was used for dichotomous variables, and the inverse variance method was used for continuous variables \[[@pone.0140565.ref022]\]. A *P* value \< 0.05 was considered statistically significant.

Statistical heterogeneity was analyzed based on the *I* ^2^ value. A *P* value \< 0.10 was considered statistically significant. An *I* ^2^ value \< 25% was considered homogeneous; an *I* ^2^ value \> 75%, as high heterogeneity; an *I* ^2^ value between 50% and 75%, as moderate heterogeneity; and an *I* ^2^ value between 25% and 50%, as low heterogeneity \[[@pone.0140565.ref022], [@pone.0140565.ref023]\]. If the *I* ^2^ value was \>50%, the studies were believed to be moderately or highly heterogeneous, and the random effects model was used to combine the effect size. If the *I* ^2^ value was \<50%, the studies were believed to be homogeneous or have low heterogeneity, and the fix effects model was used to combine the effect size \[[@pone.0140565.ref024], [@pone.0140565.ref025]\].

A sensitivity analysis was performed to evaluate the stability of the meta-analysis results. Forest plots were synthesized. Potential publication bias was investigated by using the funnel plot, Begg test, and Egger test.

A special meta-analysis was performed on the effect of metformin on body mass index (BMI) in patients with PCOS.

Results {#sec011}
=======

Search results {#sec012}
--------------

The initial search was independently executed by 2 reviewers. The details of the steps of the literature search are shown in **[Fig 1](#pone.0140565.g001){ref-type="fig"}**.

![Flow diagram of the literature search.](pone.0140565.g001){#pone.0140565.g001}

Characteristics of the Eligible Studies {#sec013}
---------------------------------------

Eighteen studies \[[@pone.0140565.ref026]--[@pone.0140565.ref043]\], with data from 744 participants, were included in this review. A total of 7 studies with 11 data sets including 280 subjects were pooled for adiponectin, 4 studies with 6 data sets including 184 subjects were pooled for resistin, 3 studies with 78 subjects were pooled for visfatin, and 10 studies with 14 data sets including 202 subjects were pooled for leptin. The characteristics of the included studies for the different adipocytokines are provided in **Tables [1](#pone.0140565.t001){ref-type="table"}--[4](#pone.0140565.t004){ref-type="table"}**, respectively. All the self-control trials included were defined as level 2, and the randomized controlled trials included were defined as level 1, according to study design \[[@pone.0140565.ref044], [@pone.0140565.ref045]\].

10.1371/journal.pone.0140565.t001

###### Characteristics of the 7 included studies on adiponectin.

![](pone.0140565.t001){#pone.0140565.t001g}

                                                                              BMI (mean ± SD)                                 
  ---------------------------------------- ------ --------- ---- ------------ ----------------- ----------- --- ----- --- --- ------
  Karen EH \[[@pone.0140565.ref027]\]      2008   America   15   27.7±1.3     43.3±2            42.3 ± 2    H   RCT   1   3   2000
  Hossam O.H \[[@pone.0140565.ref028]\]    2013   Egypt     62   29.3±4.2     30.2±4.8          29.3±2.7    H   SCT   2   6   1500
  Joanna J \[[@pone.0140565.ref029]\]      2008   Poland    29   28.24±6.27   35.32±5.07        33.49±.80   H   SCT   2   6   1000
  Aleksandra \[[@pone.0140565.ref031]\]A   2014   Poland    32   NR           26.26±5.95        25.6±5.54   H   SCT   2   3   1000
  Aleksandra \[[@pone.0140565.ref031]\]B   2014   Poland    32   NR           26.26±5.95        25.5±5.43   H   SCT   2   6   1000
  Aleksandra \[[@pone.0140565.ref031]\]C   2014   Poland    16   NR           31.19±4.44        30.2±4.06   H   SCT   2   3   1000
  leksandra \[[@pone.0140565.ref031]\]D    2014   Poland    16   NR           31.19±4.44        30.0±4.00   H   SCT   2   6   1000
  Luque RM \[[@pone.0140565.ref032]\]A     2008   Spain     10   23±5         25.0±2.8          NR          H   RCT   1   3   850
  Luque RM \[[@pone.0140565.ref032]\]B     2008   Spain     9    27±8         36.6±4.4          NR          H   RCT   1   3   850
  Charles AS \[[@pone.0140565.ref042]\]    2007   Germany   35   24.7±4.8     29.3±6.5          28.6±7.2    H   RCT   1   6   1700
  İlhan T \[[@pone.0140565.ref043]\]       2010   Turkey    24   25.21±5.99   31.69±6.52        30.7±6.65   H   SCT   2   6   1700

**Abbreviations**: SD, standard deviation; BMI, body mass index; NR, not reported; H, Have; LOE, level of evidence; SCT, self-control trials; RCT, randomized controlled trials.

10.1371/journal.pone.0140565.t002

###### Characteristics of the 4 included studies on resistin.

![](pone.0140565.t002){#pone.0140565.t002g}

                                                                               BMI (mean ± SD)                                   
  --------------------------------------- ------ ----------- ---- ------------ ----------------- ------------- --- ----- --- --- ------
  Basios G \[[@pone.0140565.ref026]\]A    2014   Greece      31   25.7 ± 6.7   \<25              NR            H   SCT   2   6   1275
  Basios G \[[@pone.0140565.ref026]\]B    2014   Greece      31   NR           25--30            NR            H   SCT   2   6   1275
  Basios G \[[@pone.0140565.ref026]\]C    2014   Greece      31   NR           \>30              NR            H   SCT   2   6   1275
  Maria M \[[@pone.0140565.ref039]\]      2011   Bulggaria   32   23.58±4.17   28.45± 4.38       27.45±3.73    H   SCT   2   3   1275
  Charles AS \[[@pone.0140565.ref042]\]   2007   Germany     35   24.7±4.8     29.3 ± 6.5        28.6 ± 7.2    H   RCT   1   6   1700
  İlhan T \[[@pone.0140565.ref043]\]      2010   Turkey      24   25.21±5.99   31.69 ± 6.52      30.7 ± 6.65   H   SCT   2   6   1700

**Abbreviations**: SD, standard deviation; BMI, body mass index; H, Have; NR, not reported; LOE, level of evidence; SCT, self-control trials; RCT, randomized controlled trials.

10.1371/journal.pone.0140565.t003

###### Characteristics of the 3 included studies on visfatin.

![](pone.0140565.t003){#pone.0140565.t003g}

                                                                             BMI (mean ± SD)                                 
  --------------------------------------- ------ --------- ---- ------------ ----------------- ----------- --- ----- --- --- ------
  Ozkaya M \[[@pone.0140565.ref040]\]     2008   Turkey    19   25.1 ± 3.8   27.1 ± 1.7        26.1±1.6    H   SCT   2   3   1700
  Charles AS \[[@pone.0140565.ref042]\]   2007   Germany   35   24.7 ± 4.8   29.3 ± 6.5        28.6±7.2    H   RCT   1   6   1700
  İlhan T \[[@pone.0140565.ref043]\]      2010   Turkey    24   25.21±5.99   31.69 ±6.52       30.7±6.65   H   SCT   2   6   1700

**Abbreviations**: SD, standard deviation; BMI, body mass index; H, have; LOE, level of evidence; SCT, self-control trials; RCT, randomized controlled trials.

10.1371/journal.pone.0140565.t004

###### Characteristics of the 10 included studies on leptin.

![](pone.0140565.t004){#pone.0140565.t004g}

                                                                                  BMI (mean ± SD)                                     
  ------------------------------------------ ------ ----------- ---- ------------ ----------------- ------------ --- ----- --- ------ ------
  Kowalska I \[[@pone.0140565.ref030]\]      2001   Poland      11   27.7 ± 1.3   34.9 ± 5.6        31.4±4.8     H   SCT   2   4--5   1500
  Luque RM \[[@pone.0140565.ref032]\]A       2008   Spain       10   23 ±5        25.0 ± 2.8        NR           H   SCT   2   3      850
  Luque RM \[[@pone.0140565.ref032]\]B       2008   Spain       9    27 ± 8       36.6 ± 4.4        NR           H   RCT   1   3      850
  Maciel GA \[[@pone.0140565.ref033]\]       2003   Brazil      7    22.5 ± 1.9   25.3 ± 2.1        24.9±2.7     H   RCT   1   6      1500
  Marciniak A \[[@pone.0140565.ref034]\] A   2009   Poland      23   NR           30.86 ± 5.35      30.39±6.1    H   SCT   2   3      1700
  Marciniak A \[[@pone.0140565.ref034]\] B   2009   Poland      12   NR           20.99 ± 1.87      20.75±1.79   H   SCT   2   3      1700
  Moran L J \[[@pone.0140565.ref035]\]       2010   Australia   29   33.5±6.7     36.1 ± 7.2        NR           H   SCT   2   6      2000
  Morin PL \[[@pone.0140565.ref036]\] A      2003   Finland     8    28.2±1.4     22.5 ± 0.8        21.7±0.7     H   RCT   1   3      1000
  Morin PL \[[@pone.0140565.ref036]\] B      2003   Finland     8    28.2 ±1.4    22.5 ± 0.8        22.1 ± 0.8   H   RCT   1   6      2000
  Morin PL \[[@pone.0140565.ref037]\] A      1998   Finland     26   30 ± 6.8     31 ± 4.6          30.66± 4.7   H   SCT   2   2      1500
  Morin PL \[[@pone.0140565.ref037]\] B      1998   Finland     12   NR           31 ± 4.6          31.7±6 5.4   H   SCT   2   4--6   1500
  Ng E H \[[@pone.0140565.ref038]\]          2001   China       8    30.5         24.1              NR           H   RCT   2   3      1500
  Maria M \[[@pone.0140565.ref039]\]         2011   Bulgaria    32   23.58±4.17   28.45±4.38        27.45±3.73   H   SCT   2   3      1275
  Romualdi D \[[@pone.0140565.ref041]\]      2008   Italy       7    23.57±6.97   32.64±4.35        31.64±3.15   H   SCT   2   4      1500

**Abbreviations**: SD, standard deviation; BMI, body mass index; NR, not reported; H, have; LOE, level of evidence; SCT, self-control trials; RCT, randomized controlled trials.

Adiponectin {#sec014}
-----------

### Selection of studies {#sec015}

There were 23 potentially eligible studies identified. Three were excluded because they did not fulfill the standard quality requirements. Thirteen studies were excluded because only median data were available. Finally, 7 studies \[[@pone.0140565.ref027]--[@pone.0140565.ref029], [@pone.0140565.ref031], [@pone.0140565.ref032], [@pone.0140565.ref042], [@pone.0140565.ref043]\] were considered as having the best available evidence.

### Main analysis {#sec016}

Seven studies, including 280 women, were eligible for the meta-analysis \[[@pone.0140565.ref027]--[@pone.0140565.ref029], [@pone.0140565.ref031], [@pone.0140565.ref032], [@pone.0140565.ref042], [@pone.0140565.ref043]\]. The *I* ^2^ value was 69%, indicating moderate heterogeneity among the included studies. Therefore, we used the random effects model to combine effect size. The meta-analysis revealed that metformin treatment was associated with a significant increases in serum adiponectin concentrations in the patients with PCOS, with a corresponding SMD of -0.43 (95% CI: -0.75 to -0.11, *P*\<0.05) (**[Fig 2](#pone.0140565.g002){ref-type="fig"}**).

![Adiponectin level.\
Adiponectin serum concentrations in the women with polycystic ovary syndrome before and after metformin treatment.](pone.0140565.g002){#pone.0140565.g002}

We also performed a special meta-analysis regarding the effect of metformin administration on BMI in patients with PCOS. The results showed that the total SMD for BMI was 0.22 units (95% CI, 0.04 to 0.39, P = 0.01) (**[Fig 3](#pone.0140565.g003){ref-type="fig"}**). The result suggests that metformin therapy was associated with a significant decrease in BMI in the women with PCOS.

![Comparison of body mass index (BMI) before and after metformin treatment in the adiponectin-related studies.](pone.0140565.g003){#pone.0140565.g003}

### Sensitivity Analysis {#sec017}

Sensitivity analysis revealed that removal of any study from the analysis did not subvert the result of the present pooled analysis (data not shown). Pooled analysis using the random effects model revealed that adiponectin levels significantly increased after metformin therapy (SMD: -0.43, 95% CI: -0.75 to -0.11, *P*\<0.05). The fixed-effects model produced a similar result (SMD: -0.43, 95% CI: -0.60 to -0.26, *P*\<0.05). Therefore, this pooled analysis outcome could be regarded with a higher degree of certainty.

### Publication bias {#sec018}

The funnel plot was not perfectly symmetrical (**[Fig 4](#pone.0140565.g004){ref-type="fig"}**), suggesting possible slight publication bias. However, Begg tests (*P* = 0.35) and Egger tests (*P* = 0.09) revealed no evidence to support publication bias in this pooled analysis. In addition, in the trim and fill method, none of the studies needed to be statistically corrected for funnel plot asymmetry.

![Adiponectin funnel plot.\
The funnel plot shows the possibility of a small publication bias. SE, standard error; SMD, standardized mean difference.](pone.0140565.g004){#pone.0140565.g004}

Resistin {#sec019}
--------

### Selection of studies {#sec020}

Seven potentially eligible studies were identified. One study was excluded, as data were not available in an extractable format. The 6 articles were then roughly screened based on their abstracts and titles, according to the inclusion/exclusion criteria. After careful discussion between the 2 reviewers, articles that fulfilled the inclusion criteria of our study were identified \[[@pone.0140565.ref026], [@pone.0140565.ref039], [@pone.0140565.ref042], [@pone.0140565.ref043]\].

### Main analysis {#sec021}

Four studies, involving 184 women, were eligible for the meta-analysis \[[@pone.0140565.ref026], [@pone.0140565.ref039], [@pone.0140565.ref042], [@pone.0140565.ref043]\]. An *I* ^2^ value of 84% indicated that high heterogeneity between the included studies. Therefore, the random effects model was performed to combine effect size. The meta-analysis revealed that circulating resistin concentration was not significantly changed after metformin treatment in the patients with PCOS, with a corresponding SMD of -0.01 (95% CI: -0.49 to 0.45, *P*\>0.05) (**[Fig 5](#pone.0140565.g005){ref-type="fig"}**).

![Resistin level.\
Resistin serum concentration in the patients with polycystic ovary syndrome before and after metformin treatment.](pone.0140565.g005){#pone.0140565.g005}

We also performed a special meta-analysis regarding the effect of metformin administration on BMI in the patients with PCOS. The results showed that the total SMD for BMI was 0.16 units (95% CI, -0.13 to 0.45, P = 0.27) (**[Fig 6](#pone.0140565.g006){ref-type="fig"}**). The result suggests that metformin therapy exerted no significant effect on BMI in the women with PCOS.

![Comparison of body mass index (BMI) before and after metformin treatment in the resistin-related studies.](pone.0140565.g006){#pone.0140565.g006}

### Sensitivity Analysis {#sec022}

Pooled analysis using the random effects model revealed that circulating resistin concentration was not significantly changed after metformin treatment in the patients with PCOS (SMD: -0.01, 95% CI: -0.49 to 0.45, *P*\>0.05). The same conclusion was reached with the fixed-effects model (SMD: -0.10, 95% CI: -0.11 to 0.31, *P*\>0.05). Meanwhile, sensitivity analysis revealed that removal of any study from the analysis did not subvert the result of the present pooled analysis (data not shown). Therefore, this pool analysis outcome could be regarded with a higher degree of certainty.

### Publication bias {#sec023}

The funnel plot was not perfectly symmetrical (**[Fig 7](#pone.0140565.g007){ref-type="fig"}**). This seems to demonstrate slight publication bias. However, Begg tests (P = 0.27) and Egger tests (P = 0.13) revealed no evidence to support publication bias in this pooled analysis. In addition, in the trim and fill method, none of the studies needed to be statistically corrected for funnel plot asymmetry.

![Resistin funnel plot.\
The funnel plot shows the possibility of a small publication bias. SE, standard error; SMD, standardized mean difference.](pone.0140565.g007){#pone.0140565.g007}

Visfatin {#sec024}
--------

### Selection of studies {#sec025}

Six potentially eligible studies were identified. Three studies were excluded because they did not fulfill the standard quality requirements. The remaining 3 studies were included in the meta-analysis \[[@pone.0140565.ref040], [@pone.0140565.ref042], [@pone.0140565.ref043]\].

### Main analysis {#sec026}

Meta-analysis included 3 studies, involving 184 women \[[@pone.0140565.ref040], [@pone.0140565.ref042], [@pone.0140565.ref043]\]. An *I* ^2^ value of 95% indicated high heterogeneity between the included studies. Therefore, the random effects model was used to combine effect size. The results showed that metformin administration did not change serum visfatin levels in the patients with PCOS, with a corresponding SMD of -0.04 (95% CI: -1.55 to 1.46, *P*\>0.05) (**[Fig 8](#pone.0140565.g008){ref-type="fig"}**).

![Visfatin level.\
Visfatin serum concentration in the women with polycystic ovary syndrome before and after metformin treatment.](pone.0140565.g008){#pone.0140565.g008}

We also performed a special meta-analysis regarding the effect of metformin administration on BMI in patients with PCOS. The results showed that the total SMD for BMI was 0.23 units (95% CI, -0.08 to 0.55, P = 0.15) (**[Fig 9](#pone.0140565.g009){ref-type="fig"}**). The result suggests that metformin therapy exerted no significant effect on BMI in the women with PCOS.

![Comparison of body mass index (BMI) before and after metformin treatment in the visfatin-related studies.](pone.0140565.g009){#pone.0140565.g009}

### Sensitivity Analysis {#sec027}

Pooled analysis using the random effects model revealed that metformin administration did not change serum visfatin levels in the patients with PCOS (SMD: -0.04, 95% CI: -1.55 to 1.46, *P*\>0.05). The fixed-effects model produced the same conclusion (SMD: -0.18, 95% CI: -0.52 to 0.15, *P*\>0.05). Conversely, sensitivity analysis showed that removal of any study from the analysis could subvert the result of the present pooled analysis (data not shown). Therefore, this pooled analysis outcome may not be regarded with a higher degree of certainty.

### Publication bias {#sec028}

The funnel plot was highly asymmetrical (**[Fig 10](#pone.0140565.g010){ref-type="fig"}**). This indicated a clear publication bias. To better understand the effect of metformin on serum visfatin concentration in patients with PCOS, a well-designed, large-scale, high-quality, multicenter randomized controlled trial is needed.

![Visfatin funnel plot.\
The funnel plot shows the possibility of a small publication bias. SE, standard error; SMD, standardized mean difference.](pone.0140565.g010){#pone.0140565.g010}

Leptin {#sec029}
------

### Selection of studies {#sec030}

We identified 35 potentially eligible studies. These studies were roughly screened based on their abstracts and titles, according to the inclusion/exclusion criteria. Twenty-two studies were excluded because they did not fulfill the standard quality requirements. Three studies were excluded because relevant data were not extractable, being available only as medians or in abstracts. Finally, 10 studies were considered as having the best available evidence \[[@pone.0140565.ref030], [@pone.0140565.ref032]--[@pone.0140565.ref039], [@pone.0140565.ref041]\].

### Main analysis {#sec031}

Meta-analysis included 10 studies, involving 202 women. An *I* ^2^ value of 70% indicated moderate heterogeneity between the included studies. Therefore, the random effects model was used to combine effect size. The meta-analysis revealed that metformin administration demonstrated an association with significantly lower leptin concentrations after treatment than before treatment in the patients with PCOS, with a corresponding SMD of 0.65 (95% CI: 0.26 to1.04, *P*\<0.05) (**[Fig 11](#pone.0140565.g011){ref-type="fig"}**).

![Leptin level.\
Leptin serum concentration in the patients with polycystic ovary syndrome before and after metformin treatment.](pone.0140565.g011){#pone.0140565.g011}

We also performed a special meta-analysis regarding the effect of metformin administration on BMI in patients with PCOS. The results showed that the total SMD for BMI was 0.35 units (95% CI, 0.12 to 0.58, P = 0.01) (**[Fig 12](#pone.0140565.g012){ref-type="fig"}**). The result suggests that metformin therapy was associated with a significant decrease in BMI in the women with PCOS.

![Comparison of body mass index (BMI) before and after metformin treatment in the leptin-related studies.](pone.0140565.g012){#pone.0140565.g012}

### Sensitivity Analysis {#sec032}

Sensitivity analysis showed that removal of any study from the analysis did not subvert the result of the present pooled analysis (data not shown). Pooled analysis using the random effects model revealed that leptin levels significantly increased after metformin therapy (SMD: 0.65, 95% CI: 0.26 to 1.04, *P*\<0.05). The fixed-effects model produced the same result (SMD: 0.61, 95% CI: 0.40 to 0.82, *P*\<0.05). Therefore, the outcome of this pool analysis could be regarded with a higher degree of certainty.

### Publication bias {#sec033}

The funnel plot was not perfectly symmetrical (**[Fig 13](#pone.0140565.g013){ref-type="fig"}**). This seemed to indicate slight publication bias. However, Begg tests (P = 0.53) and Egger tests (P = 0.29) revealed no evidence to support publication bias in this pooled analysis. In addition, in the trim and fill method, none of the studied needed to be statistically corrected for funnel plot asymmetry.

![Leptin funnel plot.\
The funnel plot shows the possibility of a small publication bias. SE, standard error; SMD, standardized mean difference.](pone.0140565.g013){#pone.0140565.g013}

Discussion {#sec034}
==========

PCOS has been repeatedly noted to be an independent risk factor of insulin resistance \[[@pone.0140565.ref046]--[@pone.0140565.ref050]\]. Thus, metformin, as the longest established oral antidiabetic agent, has been widely used in patients with PCOS to improve insulin sensitivity and induce ovulation. Adipocytokines, which are secreted by adipose tissue, may play a significant role in the pathogenesis of insulin resistance \[[@pone.0140565.ref051]\]. However, the effect of metformin on adipocytokine levels remains controversial. Some studies reported positive results \[[@pone.0140565.ref027]--[@pone.0140565.ref030], [@pone.0140565.ref034]--[@pone.0140565.ref040]\], whereas others found no significant changes in adipocytokine levels after metformin administration \[[@pone.0140565.ref026], [@pone.0140565.ref031]\].

The aim of the present study was to systematically review the literature for randomized, controlled, self-controlled trials that studied changes in the levels of adipocytokines (adiponectin, resistin, visfatin, and leptin) in patients with PCOS treated with metformin and to meta-analyze the best evidence available in order to provide high-quality data on the effect of metformin on adipocytokine levels in patients with PCOS. For this study, 34 data sets were used, including 744 patients with PCOS and adipocytokine levels measured before and after metformin administration. Thus, according to these results, metformin treatment in the patients with PCOS was associated with a significant increase in adiponectin level and decrease in leptin level, but not with the resistin and visfatin levels.

Similar to the findings of our meta-analysis, increased adiponectin levels have previously been observed in patients with PCOS who were receiving 850-mg metformin twice daily for 6 months \[[@pone.0140565.ref042], [@pone.0140565.ref043]\]. Insulin and glucose levels induced by activation of the AMP-kinase pathways have been shown to directly affect adiponectin levels \[[@pone.0140565.ref052], [@pone.0140565.ref053]\]. Increased adiponectin levels observed in patients with PCOS after metformin administration may be the result of reduced insulin resistance and insulin levels. However, inconsistent with our results, the results of another study \[[@pone.0140565.ref031]\] indicated no change in adiponectin concentration after treatment with 1000 mg of metformin daily for 6 months. These conflicting results could be explained by the relatively small sample size and difference in study populations, including differences in race, BMI, and severity of insulin resistance. Because of the complexity of the factors that influence the effect of metformin on adiponectin levels, we could not identify through our meta-analysis the precise dose or duration of metformin therapy needed to maximize the increase in adiponectin concentration in patients with PCOS. Nevertheless, based on the limited data available, our meta-analysis revealed that metformin treatment was associated with elevated serum adiponectin levels.

The role of leptin, as a marker of overall fat depots, in patients with PCOS is not well understood \[[@pone.0140565.ref054], [@pone.0140565.ref055]\]. Most studies reported higher leptin concentrations in patients with PCOS \[[@pone.0140565.ref056], [@pone.0140565.ref057]\], whereas others did not \[[@pone.0140565.ref058]\]. Various confounding factors (e.g., age and body weight) could have led to these conflicting results. Assessing the effects of the disease-specific treatment (metformin in this study) may be a way to address this issue. Based on the decreasing leptin concentrations after metformin administration in the patients with PCOS, our data seem to support the occurrence of hyperlipidemia, which is a state of leptin resistance or tolerance, in the patients with PCOS. Furthermore, leptin has been demonstrated to be associated with the development of insulin resistance and diabetes \[[@pone.0140565.ref017]\]. The result of our meta-analysis suggested that metformin administration was significantly associated with the reduction in circulation leptin concentration and that delaying or preventing the occurrence of insulin resistance and diabetes might be beneficial in patients with PCOS.

In addition, we found no significant changes in resistin or visfatin level during metformin treatment in the present study. A recent meta-analysis revealed no statistically significant differences in serum resistin and visfatin levels between patients with PCOS and control women, although serum resistin and visfatin levels were higher among both obese and normal-weight patients with PCOS than in the controls \[[@pone.0140565.ref059]\]. No correlation was observed between resistin level, BMI, homeostasis model assessment-estimated insulin resistance, area under the curve of blood insulin, insulin, lipid parameters, and serum androgen levels \[[@pone.0140565.ref060]\]. Meanwhile, Pagano and colleagues reported that insulin resistance did not lead to changes in the circulating plasma visfatin concentrations in human subjects \[[@pone.0140565.ref061]\]. These results might suggest that both resistin and visfatin levels were independently associated with insulin resistance in patients with PCOS.

Considering that more than half of the patients with PCOS had central obesity and many investigators found that metformin treatment induced a significant reduction in BMI \[[@pone.0140565.ref062]--[@pone.0140565.ref064]\], we performed a special meta-analysis regarding the effect of metformin administration on BMI in patients with PCOS for each adipocytokine. We found that metformin therapy could decrease BMI and blood concentrations of adiponectin and leptin. Moreover, we found no significant changes in BMI in the women with PCOS whose resistin and visfatin levels were unchanged. Thus, this may imply a significant correlation between the both adiponectin and leptin levels and BMI in patients with PCOS. Such results were also reported by many other authors. Orio's and Panidis's groups demonstrated a negative correlation between plasma adiponectin level and BMI in patients with PCOS \[[@pone.0140565.ref065], [@pone.0140565.ref066]\]. Similarly, the authors reported a positive correlation between plasma leptin level and BMI \[[@pone.0140565.ref067]\]. Nevertheless, the reasons for the conflicting BMI results are not clear. A possible explanation is the limited numbers and sample sizes of the studies included in the analysis of the effect of metformin on BMI in terms of resistin and visfatin levels. Meanwhile, another study reported that only about 50% of women with PCOS responded to metformin \[[@pone.0140565.ref068]\].

Although our findings are important, the limitations of our study should not be ignored. Presence of confounding variables (e.g., age, BMI, and concomitant subclinical inflammatory diseases), lack of uniformity (e.g., PCOS diagnostic criteria and assay methodology for index markers), and exclusion of studies not written in English are limitations that are difficult to avoid. Moreover, various PCOS phenotypes could not be considered. Furthermore, more studies with a large sample size would allow for precise estimation of the effect, whereas the limited numbers and sample sizes of the studies included in this analysis led to a high degree of heterogeneity in the reported resistin and visfatin levels, increasing the difficulty of interpreting the results and limiting the strength of the evidence provided by the present meta-analysis. The observed lack of effect should be interpreted as a failure to document any potential existing effect of metformin on resistin and visfatin levels in patients with PCOS rather than as evidence of no effect \[[@pone.0140565.ref069]\].

Conclusion {#sec035}
==========

The present meta-analysis demonstrates that metformin administration was associated with increased serum adiponectin concentration and decreased serum leptin levels. Further study is needed to elucidate whether this apparent effect decreases the incidence of type 2 diabetes and other metabolic diseases in patients with PCOS later in life.

Supporting Information {#sec036}
======================

###### PRISMA checklist.

(DOC)

###### 

Click here for additional data file.

[^1]: **Competing Interests:**The authors have declared that no competing interests exist.

[^2]: Conceived and designed the experiments: WK XN. Performed the experiments: WK XN. Analyzed the data: WK XN TZ ML. Contributed reagents/materials/analysis tools: LC XN WK ML. Wrote the paper: WK XN LC.
